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Abstract 
Extracellular vesicles, in particular exosomes, have recently gained interest as novel drug delivery vectors due 
to their biological origin and inherent intercellular biomolecule delivery capability. An in-depth knowledge of 
their in vivo biodistribution is therefore essential. This work aimed to develop a novel, reliable and universal 
method to radiolabel exosomes to study their in vivo biodistribution.  
Methods: Melanoma (B16F10) cells were cultured in bioreactor flasks to increase exosome yield. 
B16F10-derived exosomes (ExoB16) were isolated using ultracentrfugation onto a single sucrose cushion, and 
were characterised for size, yield, purity, exosomal markers and morphology using Nanoparticle Tracking 
Analysis (NTA), protein measurements, flow cytometry and electron microscopy. ExoB16 were radiolabelled 
using 2 different approaches – intraluminal labelling (entrapment of 111Indium via tropolone shuttling); and 
membrane labelling (chelation of 111Indium via covalently attached bifunctional chelator DTPA-anhydride). 
Labelling efficiency and stability was assessed using gel filtration and thin layer chromatography. 
Melanoma-bearing immunocompetent (C57BL/6) and immunodeficient (NSG) mice were injected 
intravenously with radiolabelled ExoB16 (1x1011 particles/mouse) followed by metabolic cages study, whole 
body SPECT-CT imaging and ex vivo gamma counting at 1, 4 and 24 h post-injection. 
Results: Membrane-labelled ExoB16 showed superior radiolabelling efficiency and radiochemical stability (19.2 
± 4.53 % and 80.4 ± 1.6 % respectively) compared to the intraluminal-labelled exosomes (4.73 ± 0.39 % and 
14.21 ± 2.76 % respectively). Using the membrane-labelling approach, the in vivo biodistribution of ExoB16 in 
melanoma-bearing C57Bl/6 mice was carried out, and was found to accumulate primarily in the liver and spleen 
(~56% and ~38% ID/gT respectively), followed by the kidneys (~3% ID/gT). ExoB16 showed minimal tumour i.e. 
self-tissue accumulation (~0.7% ID/gT). The membrane-labelling approach was also used to study ExoB16 
biodistribution in melanoma-bearing immunocompromised (NSG) mice, to compare with that in the 
immunocompetent C57Bl/6 mice. Similar biodistribution profile was observed in both C57BL/6 and NSG mice, 
where prominent accumulation was seen in liver and spleen, apart from the significantly lower tumour 
accumulation observed in the NSG mice (~0.3% ID/gT). 
Conclusion: Membrane radiolabelling of exosomes is a reliable approach that allows for accurate live imaging 
and quantitative biodistribution studies to be performed on potentially all exosome types without engineering 
parent cells. 
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Introduction 
Exosomes are a subtype of extracellular vesicles 
(EV) ranging from 50-200 nm in diameter, secreted by 
various cell types such as dendritic cells [1], 
macrophages [2], cancer cells [3-6] and mesenchymal 
stem cells [7]. Exosomes have also been shown to be 
present in various physiological fluids [8-11]. The 
combination of the inherent ability of exosomes to 
carry various biomolecules (e.g. RNA and proteins) 
[12-14] and the effective delivery of these biomolecu-
les into recipient cells [15-17] attracted interest for 
their potential as nano-scale drug delivery vectors for 
a multitude of therapeutic agents. Small molecule- 
drugs such as doxorubicin [18-20], paclitaxel [21], 
imatinib [22], curcumin [23-25], acridine orange [26] 
and anthocyanidin [27] have been demonstrated to be 
successfully loaded into exosomes and delivered to 
target cells. Nucleic acids such as siRNA [28, 29] and 
microRNA [30] have also been successfully loaded 
into exosomes via electroporation and delivered to 
target cells. Exosomes can also be engineered for 
targeted delivery, mostly by means of expressing the 
targeting moiety as a fusion protein with transmemb-
rane proteins on the exosomes [15]. The RVG 
peptide-Lamp2b fusion protein was the first to be 
demonstrated to target exosomes across the blood- 
brain barrier (BBB) for brain delivery [31]. Exosomes 
bearing the GE11 peptide-PDGFR fusion protein were 
shown to target EGFR-overexpressing breast cancer 
cell lines [32]. Interestingly, non-targeted exosomes 
have been reported to home to their tissue or cell of 
origin [33], suggesting that exosomes might have 
inherent targeting ability without requiring any 
engineering. 
Given the huge interest and potential in 
developing exosomes as drug delivery vectors, it is 
essential to understand their in vivo biodistribution. 
Several studies have been conducted to analyse this, 
mostly involving labelling exosome with fluorescent 
probes to track them in vivo via qualitative live 
imaging or quantitative ex vivo organ analysis. The 
major drawback of this technique is auto-fluorescence 
and tissue penetration depth during live imaging, 
even when using near infrared (NIR) fluorescent 
probes, therefore requiring the animals to be culled 
and organs excised for ex vivo imaging for more 
reliable results [19, 32-34]. This makes optical imaging 
limited to end-point analysis and not amenable to 
longitudinal studies or those that involve multiple 
dosing on the same animal. Ex vivo organ analysis 
using this modality also harbours substantial 
inaccuracies, as the fluorescence from the excised 
organs are detected in a 2D-manner. Combined with 
the limited tissue penetration depth of fluorescent 
probes, this results in partial loss of signals and 
therefore rendering the biodistribution analysis only 
semi-quantitative [19, 33, 34]. Labelling using lipophi-
lic dyes such as PKH26 or DiR have been reported to 
suffer from non-specific transfer of the dye between 
membranes, which heavily and adversely influenced 
the accuracy of the results obtained in the studies 
carried out [35-37]. The long half-life of these 
lipophilic dyes adds to the drawback described above, 
where it is not possible to distinguish whether the 
signal is coming from the labelled body of interest or 
free dye transferred to another membrane. Therefore, 
the reliability and accuracy of organ biodistribution of 
exosomes labelled using such dyes is questionable. 
Other modalities such as bioluminescence has 
also been explored, whereby the exosomes were 
engineered to express luciferase on their surface, 
effectively creating bioluminescent exosomes upon 
introduction of its substrate. This modality eliminates 
the problem of auto-fluorescence but requires genetic 
modification of the parent cells from which the 
exosomes originate. This can be challenging to 
perform on primary cells and is not possible for 
exosomes isolated from physiological fluids [38, 39].  
Labelling the exosomes with radioactive isotopes 
for tracking them in vivo is a more robust modality for 
evaluating both qualitative and quantitative exosome 
biodistribution via live SPECT or PET imaging and ex 
vivo organ analysis, as it does not have the limitations 
associated with the modalities described above. 
However, only a limited number of studies have been 
carried out, and in these cases the radiolabelling 
techniques suffer from serious limitation. In one 
study, the exosomes were engineered to express 
streptavidin as a fusion protein on their membrane, 
and radiolabelling was achieved when incubated with 
125I-tagged biotin [40]. Again, this method requires 
genetic modification of the parent cells and is 
therefore not applicable to all types of exosomes. 
Another study carried out radiolabelling by 
entrapping the 99mTc-HMPAO complex within the 
lumen of exosome nanomimetics (cells extruded to 
become vesicles of similar size to exosomes), via an 
in-situ glutathione-dependent reduction of the 
HMPAO chelator [41]. The success of application of 
this method to actual exosomes is uncertain as 
glutathione, the key molecule for this radiolabelling 
method, is only found in very low amounts in 
exosomes [42]. A similar method of entrapping the 
radioisotope for labelling exosomes is used in a 
different study, where the 111In-oxine complex was 
used to shuttle the 111In3+ ions inside the exosomal 
lumen [19]. Oxine however, has been discontinued as 
a commercially available radiolabelling kit. 
In this study, two novel exosome radiolabelling 
approaches using 111In3+ as the radioisotope were 
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explored. One method involves radioisotope entrap-
ment approach similar to oxine, but using tropolone, a 
safe and cheap alternative to oxine which has been 
associated with solubility and toxicity issues [43-46] as 
the ionophore for 111In3+ shuttling into the exosomal 
lumen. The second method involved covalently 
attaching DTPA-anhydride, a bifunctional chelator on 
the exosome surface that confers them the ability to 
bind 111In3+ stably. Although both of these approaches 
have been used to radiolabel cells, the properties of 
exosomes labelled by these means have not previ-
ously been evaluated. Therefore, the radiolabelling 
efficiency and stability of both approaches were 
assessed, and the approach with the most favourable 
outcome was used to study the biodistribution of 
melanoma-derived exosomes in both immunocompe-
tent and immunodeficient melanoma bearing mice, to 
investigate the effect of the mouse immune system on 
exosome biodistribution. 
Materials and Methods 
Materials 
Sterile Newborn Calf Serum Heat Inactivated 
was purchased from First Link (UK). Millex-GP 
Syringe Filter Units 0.22 µm were purchased from 
Merck Millipore (UK). Copper 300-mesh grid was 
purchased from Elektron Technologies (UK). Sodium 
chloride and glycine were purchased from VWR 
Chemicals (UK). CELLine AD1000 bioreactor flasks 
was purchased from Wheaton (UK). Indium-111 
chloride was purchased form Mallinckrodt (NL). 
Sepharose® CL-2B was purchased from GE 
Healthcare Life Sciences (UK). Sucrose, chloroform, 
magnesium sulphate and acetic acid were purchased 
from Fisher Scientific (UK). Ammonium acetate was 
purchased from Santa Cruz Biotechnology (UK). Thin 
layer chromatography (TLC) papers were purchased 
from Agilent Technologies UK Ltd (UK). Isoflurane 
(IsoFlo®) for anaesthesia was purchased from Abbott 
Laboratories (UK). PBS pH 7.4 10X, Advanced RPMI, 
penicillin/Streptomycin, GlutaMax™ 100X, Trypsin- 
EDTA 0.05%, aldehyde/sulfate latex beads 4% w/v 4 
µm and Micro BCA™ kit were purchased from 
Thermo Fisher Scientific (UK). Deuterium oxide, trop-
olone, diethylenetriaminepentaacetic dianhydride 
(DTPA-anhydride), Trypan blue 0.4%, D-(+)-Glucose 
10%, Laminin, DMEM Nutrient Mixture F-12 Ham, 
BSA and HEPES buffer were purchased from Sigma- 
Aldrich (UK). Anti-CD81 and anti-CD9 polyclonal 
primary antibodies were purchased from Bioss 
antibodies (USA). Goat anti-rabbit secondary antibo-
dy Cy5-conjugated was purchased from Abcam (UK). 
Cell culture conditions 
The murine melanoma B16F10 cells were 
cultured in Advanced RPMI 1640 medium supplem-
ented with either 10% normal or exosome-depleted 
FBS, 1% penicillin/streptomycin and 1% GlutaMax™ 
in CELLine AD1000 bioreactor flasks. Exosome- 
depleted FBS was prepared by subjecting FBS to 
ultracentrifugation at 100,000 g for 18 h at 4°C. The 
FBS supernatant post-centrifugation was collected 
and sterile-filtered using 0.22 µm filters for use in cell 
culture. Cells from 4 x T75 flasks (80% confluent) in 15 
ml medium supplemented with 10% exosome- 
depleted FBS were seeded into the cell compartment 
of 1 bioreactor flask. The medium reservoir 
compartment of the flask was filled with 500 ml of the 
medium supplemented with 10% normal FBS. Culture 
supernatant or conditioned medium (CM) was 
harvested from the cell compartment of the flask on a 
weekly basis and replaced with 15 ml of fresh 
medium supplemented with 10% exosome-depleted 
FBS. Collected CM was stored at 4°C until used for 
exosome isolation.  
Exosome isolation 
B16F10 CM was pre-cleared of dead cells and 
cellular debris by several rounds of differential centri-
fugation: 500 g for 5 minutes at 4°C (twice), then at 
2000 g for 15 minutes; followed by filtration through 
0.22 µm filter. Pre-cleared CM (22.5 ml) was added to 
polycarbonate ultracentrifuge tubes (355631, Beckman 
Coulter). Sucrose solution (25% w/w in D2O, 3 ml) 
was then carefully added to the bottom of the CM 
using glass pipettes. The ultracentrifuge tubes were 
placed in a swing-out rotor (SW45 Ti, Beckman Coult-
er) and subjected to ultracentrifugation at 100,000 g 
for 90 min at 4°C (Optima™ XPN-80, Beckman 
Coulter). Post-centrifugation, the sucrose solution (2 
ml) was withdrawn and added to 20 ml filtered PBS in 
polycarbonate ultracentrifuge bottles (355618), 
Beckman Coulter), and subjected to another round of 
ultracentrifugation in a fixed-angle rotor (Type 70 Ti, 
Beckman Coulter) at 100,000 g for 90 min at 4°C. The 
pellet obtained was resuspended in 400 µl filtered 
PBS. 
Nanoparticle Tracking Analysis (NTA) and 
protein measurements 
Exosome hydrodynamic size and number were 
measured by Nanoparticle Tracking Analysis (NTA) 
using NanoSight LM10 (Malvern Instruments, UK). 
The exosome sample was first diluted in filtered PBS 
to obtain 20-80 particles in the viewing frame. The 
modal size and particle count were measured in tripl-
icates, with 30 s as the duration for each recording, 
and analysed using the NanoSight NTA 3.2 software 
(Malvern Instruments, UK). The results were express-
ed as mean ± standard deviation (SD). Protein measu-
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rements were measured using Micro BCA™ kit. 
Flow cytometry 
Exosomes were coupled to latex microbeads 
using a protocol adapted from Théry et al. [47] prior 
to the detection of exosomal surface markers with 
flow cytometry. Briefly, 40 µl of exosomes were 
incubated with 10 µl aldehyde/sulphate latex beads 
for 15 min at room temperature (RT) before 5 µl of 100 
µM BSA solution was added to the exosome-bead 
mixture (10 µM final concentration). This was 
followed by incubation in 1 ml glycine (100 mM in 
PBS) for 30 min at RT, after which it was centrifuged 
for 5 min at 580 g and washed twice with 1 ml of 3% 
exosome-depleted FBS (made in PBS, henceforth 
referred to as 3% FBS/PBS). After the second wash, 
the pellet was resuspended in 3% FBS/PBS and 
stained with CD81 and CD9 antibodies respectively 
(rabbit anti-mouse) followed by the Cy5-conjugated 
secondary antibody (45 min each at 4°C). The bead/ 
exosome complexes were washed once with 1 ml 3% 
FBS/PBS after incubation with each antibody, and the 
pellet resuspended in an appropriate volume of 3% 
FBS/PBS. The exosome-bead complex was run on 
FACSCalibur using FL4 channel for detection of Cy5 
signals, and the results were analysed using CellQuest 
Pro software (BD Biosciences, US). A control sample 
consisting of beads only was prepared and subjected 
to the same treatment as the above but without 
staining.  
Transmission and scanning electron 
microscopy  
For transmission electron microscopy (TEM), a 
sample of exosomes was fixed in formaldehyde/ 
glutaraldehyde (2.5% each in 0.1 M sodium cacodyl-
ate buffer, pH 7.4) for 15 min. The sample was then 
placed on 300-mesh carbon-coated copper grids and 
left to air-dry. Negative staining was achieved using 
filtered aqueous uranyl acetate (25% in methanol) for 
4 min followed by two 50% methanol/H2O washes 
and left to air-dry. The grids were imaged using 
Philips CM 12 (FEI Electron Optics, NL) equipped 
with Tungsten filament and a Veleta – 2k x 2k 
side-mounted TEM CCD camera (Olympus, Japan) 
with the following settings: accelerating voltage – 80 
kV; spot size – 2; objective aperture – 150 µm. 
For scanning electron microscopy (SEM), a 
sample of exosomes was fixed in 5% glutaraldehyde 
for 2 h, which was then added on the surface of 
APTES pre-treated silicon wafer and left for 1 h. This 
was followed by washing with PBS three times and 
dehydrated in a series of increasing ethanol concent-
rations (20, 50, 70, 90, 95, 100%). The samples were 
transferred for critical drying (Samdri, Tousimis), and 
sputter coated with gold before scanning. SEM was 
performed on FEI Inspect-F (Philips, Eindhoven, NL) 
operated at 20 kV.  
Intraluminal radiolabelling of exosomes 
([111In]-ExoB16) 
Tropolone was dissolved in 200 mM HEPES 
buffered saline (HBS) pH 7-7.5 to make 1 mg/ml stock 
solution. 70-100 MBq 111InCl3 was added to 2 µg (2 µl) 
tropolone from the stock solution allowing for the 
[111In]Tropolone complex to form. The [111In]Trop 
mixture was added to exosomes (1 x 1011 particles/ 
mouse) diluted with PBS to achieve a final tropolone 
concentration of 5 µg/ml and incubated for 20 min at 
37°C. Radiolabelled exosomes ([111In]-ExoB16) were 
purified from free [111In]Trop complex by gel filtration 
using Sepharose® CL-2B as the resolving matrix, 
self-packed according to the dimensions of the com-
mercially available NAP-5™ columns, and optimised 
such that exosomes will elute in the first 2 x 500 µl 
fractions (F1 and F2). Radiolabelling efficiency was 
calculated as follows: 
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝑅𝑅𝑒𝑒𝑒𝑒𝑅𝑅𝑒𝑒𝑅𝑅𝑅𝑅𝑅𝑅𝑒𝑒𝑒𝑒 (%) = 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑟𝑟𝑟𝑟𝐴𝐴𝑟𝑟𝐴𝐴𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝐴𝐴𝑖𝑖 𝐹𝐹1 + 𝐹𝐹2
𝐼𝐼𝑖𝑖𝐴𝐴𝐴𝐴𝐴𝐴𝐼𝐼𝐼𝐼 𝐼𝐼𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑢𝑢𝑢𝑢𝑟𝑟𝑟𝑟 × 100  
Membrane radiolabelling of exosomes 
([111In]DTPA-ExoB16) 
DTPA-anhydride was added to dry chloroform 
(prepared by adding magnesium sulphate powder to 
chloroform and stirring the mixture vigorously for 2 
min, and then filtered to remove the powder) to form 
a suspension at a concentration of 1 µg/µl, with brief 
sonication to break visible clumps. The amount 
required for the reaction with exosomes was added 
into a microtube and passed under a nitrogen stream 
to evaporate the chloroform thus forming a thin film 
of DTPA-anhydride on the lining of the microtube. 
Exosomes (1 x 1011 particles/mouse in 100 µl) were 
added to the DTPA-anhydride film at a molar ratio of 
1:400 (lysine on exosome:anhydride – it was assumed 
that 1 exosome is equivalent to 1 BSA molecule i.e. 
containing 59 lysine residues) and incubated at 37°C 
for 30 min. Excess unreacted DTPA-anhydride was 
purified using Sepharose® CL-2B columns as 
described above, but using non-buffered saline as the 
elution buffer (and therefore the buffer to 
pre-equilibrate the column). 15-50 MBq of 111InCl3 was 
added to 0.2 M ammonium acetate buffer (pH 5.5) to 
achieve a final volume of 500 µl. This was then added 
to an equal volume of DTPA-ExoB16 to achieve a final 
concentration of 0.1 M ammonium acetate buffer (pH 
5.5). The mixture was incubated for 5 min at RT. 
Radiolabelled exosomes ([111In]DTPA-ExoB16) were 
purified from excess 111InCl3 using Sepharose® CL-2B 
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columns, this time using PBS as the elution buffer. The 
radiolabelling efficiency was then determined as 
described above. 
Radiochemical stability assessment 
Intraluminal-labelled exosomes 
[111In]-ExoB16 was incubated in 50% FBS or PBS 
(1:1, v/v) for 24 h at 37°C. Samples post-incubation 
were passed through Sepharose® CL-2B columns and 
the first 2 x 500 µl fractions (F1 and F2) were collected 
as described earlier. Radiochemical stability of 
[111In]-ExoB16 was calculated as follows: 
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑒𝑒ℎ𝑅𝑅𝑒𝑒𝑅𝑅𝑒𝑒𝑅𝑅𝑅𝑅 𝑠𝑠𝑠𝑠𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑠𝑠𝑒𝑒(%) =  
𝐴𝐴𝑒𝑒𝑠𝑠𝑅𝑅𝐴𝐴𝑅𝑅𝑠𝑠𝑒𝑒 𝑟𝑟𝑅𝑅𝑒𝑒𝑅𝑅𝐴𝐴𝑅𝑅𝑟𝑟𝑅𝑅𝑅𝑅 𝑅𝑅𝑅𝑅 𝐹𝐹1 +  𝐹𝐹2
𝑆𝑆𝑅𝑅𝑒𝑒𝑝𝑝𝑅𝑅𝑅𝑅 𝑅𝑅𝑒𝑒𝑠𝑠𝑅𝑅𝐴𝐴𝑅𝑅𝑠𝑠𝑒𝑒 𝑝𝑝𝑅𝑅𝑠𝑠𝑠𝑠 − 𝑅𝑅𝑅𝑅𝑒𝑒𝑖𝑖𝑅𝑅𝑅𝑅𝑠𝑠𝑅𝑅𝑅𝑅𝑅𝑅  × 100 
Membrane-labelled exosomes 
[111In]DTPA-ExoB16 was incubated in 50% FBS or 
PBS as described above, and samples post-incubation 
were then spotted on thin layer chromatography 
(TLC) paper strips impregnated with silica gel. The 
strips were eluted with 0.1 M ammonium acetate 
containing 0.25 mM EDTA (pH 5.5) and analysed on a 
phosphor imager (Cyclone® Packard, Australia). The 
percentage of 111In still attached to exosomes (imm-
obile spot at the application point) was considered as 
the radiochemically stable [111In]DTPA-ExoB16. 
Animal models 
All animal experiments were performed in 
compliance with the UK Home Office Animals 
(Scientific Procedures) Act 1986. Female C57Bl/6 mice 
and male NOD SCID gamma (NSG) mice (~20 g, 6-8 
weeks old) were obtained from Charles River (UK). 
Subcutaneous (SC) tumours were established by 
inoculating B16F10 cells (1 x 106 cells in 100 µl PBS) 
subcutaneously into the left and right rear flanks of 
the mice. The mice were monitored closely post- 
inoculation and were used for studies when the 
tumours reached ~200-300 mm3. 
Whole body SPECT/CT imaging of 
radiolabelled exosomes  
For intraluminal-labelled exosomes, C57Bl/6 
mice (n=3 per treatment) was injected intravenously 
via the tail vein with 1 x 1011 [111In]-ExoB16 (5-10 MBq) 
or the equivalent amount of radioactivity of free 
[111In]Trop. For membrane-labelled exosomes, C57Bl/ 
6 mice (n=3 per treatment) was injected with 1 x 1011 
[111In]DTPA-ExoB16 (5 – 10 MBq) or the equivalent 
amount of radioactivity of free [111In]DTPA. Mice 
were imaged under anaesthesia (2% isoflurane in air) 
in prone position on a heating pad at 37°C using a 
nanoSPECT/CT four-head scanner (Bioscan, USA). 
SPECT images were obtained at 0-30 min, 4 h and 24 h 
post-injection using 1.4 mm pinhole collimators (24 
projections, 60 s per projection; 30 min scan) and CT 
images were obtained at the end of each SPECT 
acquisition using an X-ray source setting of 45 kVp. 
All data were reconstructed with proprietary Bioscan 
software and SPECT and CT acquisitions were fused 
using PMOD® software (Mediso). Mice were culled 
and disposed of after the 24 h imaging. 
Ex vivo gamma counting of excised 
organs/tissue  
Similar to SPECT/CT imaging, mice were 
injected intravenously with 1 x 1011 [111In]-ExoB16 (0.5 – 
1 MBq) or free [111In]Trop of equivalent radioactivity; 
and 1 x 1011 [111In]DTPA-ExoB16 (0.5 – 1 MBq) or free 
[111In]DTPA of equivalent radioactivity. Blood 
samples (5 µl from the tail vein) were taken at various 
time points (2, 5, 10, 30, 60, 240 and 1440 min) to 
analyse the exosome circulation profile. Urine and 
faeces were collected by housing the mice in 
metabolic cages for 24 h to analyse the excretion 
profile. After 1, 4 and 24 h, mice were sacrificed (n=3 
per time point) and perfused with heparinised saline 
(1000U/l, 25 ml per animal). Major organs (brain, 
lungs, liver, spleen, kidneys, heart, and stomach), 
muscle, skin, bone (femur), carcass and tumours were 
collected, weighed and placed in scintillation vials. 
Samples were counted in a gamma counter (LKB 
Wallac 1282 Compugamma, PerkinElmer, UK) 
together with radioactive dose standards. Radioacti-
vity readings (counts per minute – CPM) were 
expressed as percentage of injected dose per organ 
(%ID/organ) or percentage of injected dose per gram 
of tissue (%ID/gT). Data were expressed as the mean 
± SD of sample triplicates. 
Statistical analyses 
For all experiments, data were presented as 
mean ± SD, where n denotes the number of repeats. 
Statistical significance of the data was assessed using 
Student’s t-test and is designated with asterisk(s) 
(p* < 0.05, p**< 0.01, and p***< 0.001). 
Results 
Exosome isolation and physicochemical 
characterisation 
Cancer cell lines are known to be good exosome 
producers [3-6] and hence they were selected as exos-
ome sources in this study. Exosomes were isolated 
from B16F10 cells (murine melanoma) cultured in a 
bioreactor flask (CELLine AD1000) which can help 
increase the yield of exosomes [48]. The culture 
supernatant, hereby referred to as conditioned 
medium (CM) was harvested on a weekly basis. CM 
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initially underwent pre-clearing to remove dead cells 
and cellular debris by a series of differential centrifu-
gation and ultrafiltration. Pre-cleared CM was then 
subjected to ultracentrifugation onto a sucrose 
cushion to separate exosome from proteins by density 
in the CM, followed by a washing step to remove the 
sucrose and residual contaminating proteins. The 
resulting exosome pellet was resuspended in a small 
volume of PBS (400 µl) to make a concentrated 
exosome stock.  
The physicochemical characterisation of 
exosomes isolated from B16F10 (ExoB16) cells are 
summarised in Table 1. The size measured using 
NanoSight was 132.3 ± 5.6 nm, which compares to 
other exosome studies. Particle concentration 
quantification (also using NanoSight) showed that 
B16F10 cells are a prolific exosome producer, yielding 
2.04 x 1013 ± 3.9 x 1012 p/ml from 72 ml of CM (obtain-
ed from 6 rounds of CM collection from a single 
bioreactor flask). A measure of purity of the ExoB16 
from contaminating proteins was also carried out by 
means of calculating the particle to protein (P:P) ratio 
of the isolated exosome stock. The P:P ratio was found 
to be 4.52 x 1010 ± 1.26 x 1010 p/µg protein, which falls 
in the proposed range of high purity level [48]. 
Biochemical and morphological analysis of 
ExoB16 
Detection of exosomal markers was achieved 
using flow cytometry as previously described [49]. 
The isolated ExoB16 expressed CD81 and CD9, which is 
a common property of exosomal vesicles (Fig. 1A and 
Fig. S1). Morphological analysis of ExoB16 was also 
undertaken using both transmission electron microsc-
opy (TEM) and scanning electron microscopy (SEM), 
which can also validate the size measurement obtain-
ed from NanoSight. Both TEM and SEM images of 
ExoB16 demonstrated that the exosomes were spherical 
structures slightly above 100 nm in size (Fig. 1B). 
 
Table 1. Physicochemical characterisation of exosomes 
Exosome Size1,2 
(nm) 
Yield1,2,3 
(p/ml) 
[Protein]2,4 
(µg/ml) 
Particle to protein (P:P) ratio2,5 
(p/µg) 
B16F10 132.3 ± 
5.6 
2.04x1013 
± 3.9x1012 
451.15 ± 71.5 4.52x1010 ± 1.26 x1010 
1Measured using NanoSight LM10. 2Values are expressed as mean ± SD, where n=3. 
3Yield was obtained by cell-conditioned medium pooled from 6 rounds of 
harvesting from CELLine AD1000 flasks (72 ml). 4Measured using BCA assay. 
5Value obtained by using formula: P:P ratio = Yield / [Protein]. 
 
Intraluminal radiolabelling of ExoB16 
Radiolabelling efficiency and stability 
The intraluminal radiolabelling 
approach is achieved via the ability of the 
small hydrophobic molecule called trop-
olone to chelate radionuclides and form a 
complex that allows the radionuclide to 
diffuse across the exosomal membrane 
and into the exosomal lumen, similar to 
its predecessor oxine [50]. This method, 
particularly utilising the 111Indium- 
tropolone complex ([111In]Trop) has been 
widely used to radiolabel cellular compo-
nents of blood such as platelets [43, 44], 
lymphocytes [45, 51] and granulocytes 
[52] for in vivo imaging. Other cell types 
such as mesenchymal stem cells [53, 54] 
and endometrial cells [55] have also been 
successfully radiolabelled using [111In] 
Trop. More recently, [111In]Trop was used 
to label polymeric micelles [56]. The 
orientation of exosomal transmembrane 
proteins is the same as their parent cells 
[15] and therefore provides the opportu-
nity for them to be radiolabelled using the 
same principle. The mechanism by which 
this intraluminal radiolabelling is achie-
ved is summarised in Scheme 1A. 
Tropolone is firstly mixed with 111Indium 
(as 111InCl3) to allow for the formation of 
the of the [111In]tropolone complex. The 
 
 
Figure 1. Biochemical and morphology analysis of B16F10 exosomes. (A) Detection of 
exosomal markers CD81 and CD9 using flow cytometry on exosomes isolated from B16F10 cells. 
Exosomes were coupled to aldehyde/sulphate latex beads prior to detection. Exo-beads complex 
were subsequently stained using a 2-step labelling (anti-CD81 or anti-CD9 1° ab/Cy5-conjugated 2° 
ab). Degree of expression of the markers are expressed as the fold difference in median 
fluorescence intensity (MFI) values from that of the control (exo-beads complex stained with 
Cy5-conjugated 2° ab). Values are expressed as mean ± SD, where n=3. (B) Transmission electron 
microscopy (TEM) and scanning electron microscopy (SEM) images of exosomes isolated from 
B16F10 cells. 
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chemical structure of tropolone and [111In]Trop 
complex is illustrated in Scheme S1A and S1B 
(supplementary information). Upon incubation with 
exosomes, [111In] Trop gets translocated into the 
exosomal lumen, forming the intermediate 
[111In]Trop-ExoB16. Upon entry, 111In3+ exchanges to 
bind with cytoplasmic biomolecules of at least 3.6 kDa 
[50]. As the interaction between 111In3+ and tropolone 
is not particularly strong, 111In3+ from the [111In]Trop 
will then exchange with proteins and nucleic acids 
within the exosomal lumen [50]. Free tropolone 
molecules leave the exosomal lumen and the 111In3+ is 
now entrapped within the lumen, thereby resulting in 
radiolabelled exosomes ([111In]-ExoB16). 
Purification of excess [111In]Trop from [111In]- 
ExoB16 was carried out via gel filtration using Sephar-
ose® CL-2B as the resin. Free [111In]Trop was used as a 
control and the elution profiles of both [111In]-ExoB16 
and [111In]Trop were analysed. Exosomes were found 
to elute in F1 and F2 (Fig. S2A and S2B) while 
[111In]Trop mainly eluted in F4 and F5 (Fig. 2A). The 
percentage (%) radiolabelling for [111In]-ExoB16 was 
4.73 ± 0.39% compared to only 0.20 ± 0.04% (p<0.05) 
for [111In]Trop collected in F1+F2 (Fig. 2A). 
[111In]-ExoB16 were incubated in either PBS or 
50% serum at 37°C for 24 h to assess the radiochemical 
stability of the labelling. The typical method of 
assessing the labelling stability is using thin layer 
chromatography (TLC), by measuring the % activity 
that did not migrate with the mobile phase and 
remains at the application point after 24 h incubation, 
corresponding to radiolabelled macromolecules 
[57-59]. It was not possible to apply this method to 
assess the intraluminal labelling stability of exosomes 
as [111In]Trop will not migrate using 0.1 M ammonium 
acetate with 0.25 mM EDTA, pH 5.5 mobile phase, 
rendering it impossible discern whether the % activity 
remaining at the application point is originating from 
that of radiolabelled exosomes or free [111In]Trop. An 
alternative approach was used by passing sample 
post-incubation through Sepharose® CL-2B column 
used previously to determine radiolabelling efficien-
cy. The stability of intraluminal-labelled [111In]-ExoB16 
was found to be 43.35 ± 10.12% and 14.21 ± 2.76% in 
PBS and 50% serum, respectively, at 24 h 
post incubation (Fig. 2B). 
 Biodistribution of intraluminal-labelled 
[111In]- ExoB16 was assessed qualitatively and 
quantitatively using whole body SPECT/CT 
imaging and ex vivo gamma counting, 
respectively. Significant difference was 
observed in the organ accumulation profile 
of [111In]-ExoB16 as compared to that of free 
[111In]Trop, which further supports the 
successful radiolabelling of the exosomes 
(Fig. S3, S4 and S5). However, due to the 
low stability of the intraluminal-labelled 
[111In]-ExoB16, the reliability and accuracy of 
the organ accumulation values, especially 
that of the tumours were deemed 
improbable. 
Membrane radiolabelling of ExoB16 
Radiolabelling efficiency and stability 
Membrane radiolabelling was achieved 
by covalently attaching the bifunctional 
chelator DTPA- anhydride to the exosome 
surface in an amine- dependent reaction. 
Exosome membranes contain various 
transmembrane proteins which are likely to 
have free amines (from lysine residues) on 
the extraluminal domain. The schematics of 
the reaction are summarised in Scheme 1B. 
The free amines act as nucleophiles that 
attack anhydrides on the DTPA, resulting in 
exosomes with covalently attached DTPA on 
their surface via amide bonds (DTPA-ExoB16). 
 
 
Scheme 1. (A) Intraluminal and (B) membrane radiolabelling protocols of B16F10 exosomes 
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Incubating DTPA-ExoB16 with 111Indium (as 111InCl3) 
will then allow 111In3+ to be chelated by DTPA on the 
exosomes, thereby radiolabelling the exosomes 
([111In]DTPA-ExoB16). The chemical structure of 
DTPA-anhydride and its reaction with exosomal 
amine is illustrated in Scheme S1C and S1D 
respectively (supplementary information). 
Radiolabelling efficiency of membrane-labelled 
exosomes was assessed in a similar manner to that of 
intraluminal labelling, where free 111In in 0.2M 
ammonium acetate buffer pH 5.5 (111In-AA) and 
[111In]DTPA-ExoB16 were eluted through Sepharose® 
CL-2B columns and their respective elution profiles 
analysed. Radiolabelling efficiency was determined as 
the % radioactivity recovered in F1+F2. 111In-AA and 
[111In]DTPA-ExoB16 showed similar elution profile, but 
unlike that observed with intraluminal labelling, % 
activity eluted in F4 and F5 were less than that of F1 
and F2, with higher % activity being retained in the 
column post-elution (Fig. 3A). Percentage (%) activity 
recovered in F1+F2 for [111In]DTPA-ExoB16 was 
significantly higher than that of 111In-AA (19.2 ± 4.53% 
and 0.02 ± 0.001% respectively), thereby confirming 
that the activity recovered in F1+F2 were from 
[111In]DTPA-ExoB16. The radiolabelling efficiency of 
[111In]DTPA-ExoB16 considered to be 19.2 ± 4.53 % was 
significantly higher than that obtained by 
intraluminal-labelling method (Fig. 2A). 
Radiochemical stability of [111In]DTPA-ExoB16 in 
PBS and 50% serum after 24 h at 37°C was assessed 
using TLC as explained above, by measuring the % 
activity that did not migrate with the mobile phase 
(0.1 M ammonium acetate with 0.25 mM EDTA, pH 
5.5) and remained at the application point, correspo-
nding to radiolabelled exosomes. Free In3+ was also 
run on the TLC paper as a control, where they all 
migrate to the solvent front as they were chelated by 
EDTA present in the mobile phase (Fig. 3B). The 
stability of [111In]DTPA-ExoB16 in PBS and 50% serum 
was ~87 % and ~80% respectively, both higher than 
that of intraluminal-labelled exosomes (Fig. 2B). 
Whole body SPECT/CT live imaging 
Free [111In]DTPA and [111In]DTPA-ExoB16 were 
injected intravenously into C57Bl/6 mice bearing 
subcutaneous B16F10 tumours (1x1011 particles 
per animal for [111In]DTPA-ExoB16) for whole 
body SPECT/CT imaging, of which the former 
acts as a control to ensure the signals detected in 
vivo were coming from [111In]DTPA- ExoB16 and 
not from free circulating [111In]DTPA that was 
cleaved from the exosome surface. Imaging was 
undertaken immediately, 4 h and 24 h post- 
injection. Imaging results showed a significant 
difference between the biodistribution profile of 
[111In]DTPA and [111In]DTPA- ExoB16 (Fig. 4). At 
0-30 min post-injection, high amounts of 
[111In]DTPA can be seen in kidneys and bladder 
indicating high urinary excretion, but at 4 h the 
signals can only be seen in the bladder, which 
then becomes too low to be detected at 24 h. In 
contrast, [111In]DTPA-ExoB16 showed very high 
signals in the liver and spleen at 0-30 min 
post-injection, which remained up to 24 h. Some 
signals detected in the bladder at the earlier 
timepoints, and tumour accumulation was not 
observed. The clear distinction between the in 
vivo imaging results of [111In]DTPA and 
[111In]DTPA-ExoB16 corroborated the finding that 
the % activity recovered in F1+F2 from Fig. 3A 
originated from labelled exosomes and confirms 
successful membrane radiolabelling of exosomes.  
Quantitative organ biodistribution by gamma 
counting 
Quantitative biodistribution analysis of 
both [111In]DTPA and [111In]DTPA-ExoB16 at 1, 4 
 
 
Figure 2. Radiolabelling efficiency and radiochemical stability of 
intraluminal-labelled B16F10 exosomes. (A) Radiolabelled exosomes 
([111In]-ExoB16) were purified from excess [111In]Trop complex by gel filtration 
(Sepharose® CL-2B). Eight 500 µl fractions were collected and the radioactivity for each 
fraction and the column itself post-purification was measured by gamma counting, and 
are expressed as the percentage of activity relative to the initial activity added to the 
column. Radiolabelling efficiency was calculated as the sum of % radioactivity recovered 
from F1 and F2. (B) Radiolabelled exosomes were incubated in either PBS or 50% serum 
for 24 h at 37°C, and then passed through the same column as (A). Eight 500 µl fractions 
were collected and the radioactivity for each fraction and the column itself (FC) 
post-purification was measured using gamma counter, and are expressed as the 
percentage of activity relative to the activity of the sample added to the column. 
Radiochemical stability was calculated as the sum of % radioactivity recovered from F1 
and F2. Values are expressed as mean ± SD, where n=3. Statistical analysis was done on 
F1 and F2 (p* < 0.05, p*** <0.001). 
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and 24 h was also carried out by gamma counting as 
per described above. Both [111In]DTPA and 
[111In]DTPA- ExoB16 were found to be cleared rapidly 
from the circulation with only ~16.2% injected dose 
(ID) and ~10.5% ID respectively remaining after only 
2 min post-injection and reaching a very low level of 
1% or slightly less in just 1 h (Fig. 5A). Although both 
free [111In]DTPA and [111In]DTPA-ExoB16 showed 
rapid clearance from the circulation, they showed 
significantly different kinetics especially in the earlier 
timepoints (<60 min). As expected, a significantly 
much higher amount of [111In]DTPA (~92.6% ID) was 
excreted in the urine as compared to that of 
[111In]DTPA-ExoB16 (~4.93% ID), but the amount 
excreted in faeces was similarly low for both 
compounds with a value of ~1-4 % ID (Fig. 5B). 
Looking at organ biodistribution, there was minimal 
accumulation of [111In]DTPA with ~2.0 % ID per gram 
tissue (ID/gT) or lower across all organs including 
tumours, which recorded a value of about ~0.2 – 0.4 % 
ID/gT (Fig. 5C). In contrast, [111In]DTPA-ExoB16 
showed high accumulation in the liver with ~66.0% 
ID/gT at 1 and 4 h, which then decreased slightly to 
~56.0 % ID/gT after 24 h, of which the difference is 
not significant (Fig. 5D). This was followed by spleen, 
which showed an accumulation of ~26.0% ID/gT at 1 
and 4 h, which increased slightly but not significantly 
to ~37.7% ID/gT. Kidneys showed an accumulation of 
~2.5 % ID/gT of [111In]DTPA-ExoB16 after 24 h. 
Tumour accumulation of [111In]DTPA-ExoB16 was 
initially very low but showed a steady increase, 
reaching a value of ~0.7 % ID/gT after 24 h. When 
comparing organ biodistribution values at 24 h, a 
significant difference can be observed between that of 
[111In]DTPA and [111In]DTPA-ExoB16, where the latter 
shows a significantly higher liver, spleen and tumour 
accumulation as compared to that of the former (Fig. 
5E), which reflects successful and stable radiolabelling 
of ExoB16. The quantitative biodistribution results of 
both free [111In]DTPA and [111In]DTPA-ExoB16 
expressed as %ID/organ are summarised in Fig. S6 
(supplementary information). In summary, results 
from membrane-labelled exosomes, espe-
cially the quantitative organ accumulation 
values, were deemed as more reliable due 
to its superior radiochemical stability 
(thus higher signal-to-noise ratio) and is 
selected as the approach for the 
subsequent part of the study. 
Comparative biodistribution of 
ExoB16 in immunocompetent and 
immunodeficient mice  
Next, membrane-labelled exosomes 
were injected into NOD-scid ILR2γnull 
(NSG) mice to study the influence of the 
immune system on the in vivo biodistrib-
ution of exosomes. [111In]DTPA-ExoB16 
(1x1011 particles per animal) were injected 
intravenously into NSG mice bearing 
subcutaneous B16F10 tumours and 
quantitative biodistribution analysis at 1, 
4 and 24 h was carried out as the above via 
gamma counting. [111In]DTPA-ExoB16 
showed a similar blood circulation profile 
in NSG mice when compared to that in 
C57Bl/6 mice, where [111In]DTPA-ExoB16 
was cleared rapidly from the circulation 
with only ~15.3% ID remaining at 2 min 
post-injection, which decreased to ~0.1% 
ID after 24 h (Fig. 6A). [111In]DTPA-ExoB16 
in NSG mice also showed similar amounts 
of excretion via the urine and faeces to 
that of C57BL/6 mice (Fig. 6B). 
[111In]DTPA-ExoB16 in NSG mice also 
showed a similar pattern of organ 
 
 
Figure 3. Radiolabelling efficiency and radiochemical stability of membrane-labelled 
B16F10 exosomes. (A) B16F10 exosomes with covalently attached DTPA (DTPA-ExoB16) were 
purified from excess 111InCl3 by gel filtration (Sepharose® CL-2B). Free 111In in ammonium acetate 
buffer (111In-AA) was also eluted through the column as control. Eight 500 µl fractions were 
collected and the radioactivity for each fraction and the column itself post-purification was 
measured by gamma counting, and are expressed as the percentage of activity relative to the initial 
activity added to the column. Radiolabelling efficiency was calculated as the sum of % radioactivity 
recovered from F1 and F2. Values are expressed as mean ± SD, where n=3. Statistical analysis was 
done on F1 and F2 (p** < 0.01, p*** <0.001). (B) Radiolabelled exosomes ([111In]DTPA-ExoB16) 
were incubated in either PBS or 50% serum for 24 h at 37°C, and then spotted on a TLC paper. The 
paper was then run on 0.1 M ammonium acetate with 0.25mM EDTA (pH 5.5) as the mobile phase 
and imaged using a phosphorimager. Radiochemical stability was calculated as % radioactivity 
remaining at the application point. Values are expressed as mean ± SD, where n=3. 
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accumulation to that in C57BL/6 mice across the time 
points, where the liver recorded the highest signals 
with ~48.3% ID/gT at 1 h, which then decreased 
slightly to ~40.0% ID/gT at 4 and 24 h (Fig. 6C). 
Spleen recorded the second highest accumulation of 
~13.0 % ID/gT at 1 and 4 h, which then increased 
significantly to ~45.8 % after 24 h. [111In]DTPA-ExoB16 
accumulation in the kidneys showed a steady increase 
over the timepoints, reaching a value of ~6.8 % ID/gT 
after 24 h. The tumours showed an accumulation of 
around ~0.4 % ID/gT at 1 and 4 h, which then 
decreased slightly to ~0.3 % ID/gT after 24 h. 
Comparing biodistribution values at 24 h showed that 
[111In]DTPA-ExoB16 accumulation in C57BL/6 and 
NSG mice recorded similar values across the different 
organs, especially in the liver, spleen and kidneys 
(Fig. 6D). [111In]DTPA-ExoB16 in NSG mice however 
showed a significantly lower tumour accumulation as 
compared to that in C57BL/6 mice. In summary, 
exosomes show a similar pattern of organ accumu-
lation in both immunocompetent and immunodefi-
cient mouse models with the exception of tumour, in 
which the accumulation in the latter was lower. 
Discussion 
As described earlier, exosomes are very similar 
to cells in terms of being a phospholipid bilayer 
system, having the same membrane topology as their 
parent cells and inherently containing biomolecules 
such as proteins and RNAs as their cargo [15]. 
Therefore, [111In]Trop was hypothesised to result in 
successful radiolabelling of exosomes. This approach 
did lead to successful radiolabelling of the exosomes 
as described earlier, but at a much lower efficiency 
compared to that observed in platelets of ~60-80% 
[43]. Assuming platelet size to be 1 µm in diameter 
[60] and that of ExoB16 is ~130 nm (Table 1), and that 
both are perfect spheres, the number of ExoB16 used in 
this study to determine the radiolabelling efficiency (3 
x 1011 particles) accounts for a total surface area which 
is about double that of the platelets used in 
the above study (2.2 x 109 platelets). However, 
the volume of an ExoB16 particle is ~45 times 
lower than that of a single platelet. Therefore, 
although [111In] Trop complexes were able to 
translocate efficiently into the exosomal 
lumen due to the large total surface area, their 
significantly lower volume suggests a much 
lower amount of biomolecules within the 
exosomal lumen for 111In3+ to exchange with 
as compared to that in the cytoplasm of 
platelets. 111In3+ translocated into the exoso-
mal lumen probably largely still exists as 
[111In]Trop due to the lack of biomolecules for 
exchange and are well able to leave the 
exosomal lumen, forming an equilibrium in 
terms of its concentration within and outside 
the lumen, contributing to the low radiolab-
elling efficiency and stability. This is 
corroborated by the similar radioactivity 
detected in the tumours of mice injected with 
111In-ExoB16 24 h post-injection and that of the 
mice injected with free [111In]Trop, suggesting 
that the unexchanged 111In3+ in the form of 
[111In]Trop leaked out from the exosomal 
lumen into the circulation and gradually 
accumulates in the tumour (Fig. S4C & S4D). 
Another possibility for the low serum 
stability observed with intraluminal- labelled 
exosomes is that the serum might be 
damaging the vesicles, thereby releasing the 
entrapped [111In]Trop. However, this possibi-
lity is ruled out as very good serum stability 
was observed with the membrane-labelled 
exosomes (Fig. 3B). 
 
 
Figure 4. Whole body SPECT/CT imaging of membrane-labelled B16F10 
exosomes in melanoma-bearing C57Bl/6 mice. (A) Animal was injected intravenously 
with free [111In]DTPA complex as control. (B) Animal was injected with [111In]DTPA-ExoB16. 
Imaging was done immediately, 4, and 24 h post-injection. White circles indicate the position 
of tumours. 
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 The membrane or surface radiolabelling appro-
ach has been employed in synthetic nanocarriers such 
as polymeric nanocapsules and liposomes, whereby 
strong radioisotope chelators such as DTPA is 
incorporated as an integral component of their 
polymeric shell or membrane respectively during 
synthesis. This allows the nanocarriers to be 
radiolabelled when incubated with radioisotopes such 
as 111In3+, with their radiolabelling efficiency and 
stability reported to be between 61.9-100% and 
78.2-91.3% respectively [57, 58, 61]. This strategy of 
DTPA incorporation however is not possible on 
biomolecules such as exosomes, and so bifunctional 
chelators are used instead. Bifunctional chelators are 
molecules that consist of a strong chelating agent such 
as DTPA on one end, and a biologically-reactive 
functional group on the other end, usually amine- 
reactive groups such as NHS-ester or anhydride, or 
thiol-reactive groups such as maleimide [62]. One 
such bifunctional chelator, cyclic DTPA- dianhydride 
(hereon referred to as DTPA-anhydride) 
was successfully conjugated to human 
serum albumin in a simple and rapid 
reaction, which allows subsequent radiola-
belling with 111In3+ and its biodistribution 
analysed quantitatively [63]. DTPA- 
anhydride has since been demonstrated to 
be successfully conjugated to other biomol-
ecules such as fibrinogen [64] and 
antibodies [65-68] without losing their 
specificity and function, enabling quantita-
tive analysis of their biodistribution. This 
same DTPA-anhydride, which is now 
commercially available, was adopted in this 
study where it was conjugated to ExoB16, 
and a 5-fold increase in both radiolabelling 
efficiency and stability was observed (Fig. 
3A & 3B).  
Radiolabelling stability of [111In] 
DTPA-ExoB16 was similar to that reported in 
the studies above, and this was expected as 
DTPA is attached to exosomes via the same 
stable amide bond. The radiolabelling 
efficiency of [111In]DTPA-ExoB16 however is 
lower than that reported for the other 
nanocarriers, and this could be due to a 
lower number of DTPA molecules 
conjugated to ExoB16. In principle, this 
could be overcome by increasing the molar 
ratio of DTPA- anhydride in the reaction 
with the exosomes. However this would 
pose a problem due to rendering the 
reaction mixture more acidic due to the 
increasing amount of free DTPA forming 
from spontaneous hydrolysis in aqueous 
solution [68]. Given that the pKa of the 
side-chain amine on a lysine residue is 
~10.5, low pH conditions would easily 
increase the proportion of the protonated 
form of the free amines of the lysine 
residues on the exosomal surface, making 
them weaker nucleophiles and thereby 
reducing the efficiency of the reaction [68]. 
This low pH could also adversely affect the 
function and integrity of other exosomal 
 
 
Figure 5. Blood circulation, excretion and organ biodistribution profiles of 
membrane-labelled B16F10 exosomes in melanoma-bearing C57Bl/6 mice. The 
[111In]DTPA group was injected with 0.02M DTPA complexed with 0.5-1MBq of 111InCl3 while 
the [111In]DTPA- ExoB16 group was injected with 1x1011 [111In]DTPA-ExoB16 (0.5-1MBq). (A) 
Blood circulation profile of [111In]DTPA and [111In]DTPA-ExoB16. 5 µl blood were taken via tail 
bleeding at 2 min, 5 min, 10 min, 30 min, 1 h, 4 h and 24 h following intravenous injection of each 
compound. (B) Excretion profile of [111In]DTPA and [111In]DTPA-ExoB16 where urine and faeces 
were collected from the animals 24 h post-injection. (C) and (D) Organ biodistribution of 
[111In]DTPA and [111In]DTPA-ExoB16 respectively. Animals were culled at 1 h, 4 h and 24 h 
post-injection, perfused with saline and their organs were excised for analysis by gamma 
counting. Inset shows the zoomed-in tumour accumulation values for each group. (E) 
Comparison of organ biodistribution of [111In]DTPA and [111In]DTPA-ExoB16 24 h post-injection, 
where inset shows zoomed-in tumour accumulation values for each group. Values are 
normalised to organ weight and expressed as mean ± SD, where n=3 for each group. For (C), 
(D) and (E), statistical analyses were done on liver, spleen, kidneys and tumour (p*<0.05, p** < 
0.01, p*** <0.001). 
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transmembrane proteins, which could affect the 
biodistribution as they have been reported to play a 
role in cell uptake [69-71]. This is corroborated by 
studies that reported antibodies reacted with a high 
ratio of DTPA-anhydride had reduced antigen 
binding ability [65, 68]. It is therefore important to 
determine the number of free amines on exosomal 
surface prior to the reaction with DTPA. This is 
challenging due to the heterogeneity of exosomes, 
even the ones isolated from the same source. In this 
study, the number of free amines i.e. lysine residues 
on exosomes was assumed to be similar to that of 
bovine serum albumin (BSA) and this was used as the 
basis for reaction with DTPA-anhydride. In our 
hands, reactions using 1:80, 1:200, 1:400 and 1:800 
(Lys:anhydride) molar ratios showed increasing 
radiolabelling efficiency with increasing molar ratio 
up to 1:400 (data not shown) after which a decline was 
observed. The molar ratio 1:400 was therefore chosen 
for the DTPA-ExoB16 conjugation in this study. 
 Contaminating proteins from serum used in 
culture such as albumin and present in the ExoB16 
sample [48], are likely to compete with the exosomes 
for the reaction with DTPA-anhydride [63], thus 
lowering ExoB16 labelling efficiency. Purifying 
exosome samples by gel filtration (e.g. Sepharose® 
CL-2B used in this study) or centrifugal filters (e.g. 
Nanosep®) prior to the labelling reaction can 
significantly reduce the amount of contaminating 
proteins in the sample, but this results in substantial 
loss of ~50% exosomes post-purification (Fig. S7A 
and Fig. S7B). This can pose a serious challenge when 
working with a limited number of exosomes either 
obtained from cell cultures or liquid biopsies. Gel 
filtration using Sepharose® CL-2B resin as the 
resolving matrix was chosen in this study due to its 
superior contaminating protein removal 
performance and thus significantly 
better improvement in the P:P ratio of 
the exosome sample, without altering the 
size of the exosomes (Fig. S7B, Fig. S7C 
and Fig. S7D). Hence, in case that 
DTPA-conjugated proteins were formed, 
they could be efficiently removed along 
with excess unreacted DTPA-anhydride 
post-reaction prior to incubation with 
111In3+. The radiolabelling efficiency of 
[111In]DTPA-ExoB16 achieved in this study 
(Fig. 3A) was compliant to the “As Low 
As Reasonably Practicable” (ALARP) 
principle outlined by the UK’s Health 
and Safety Executive (HSE) in terms of 
radioactivity required to perform 
SPECT/CT imaging and quantitative 
biodistribution studies.  
 As mentioned earlier, exosomal 
surface proteins play an important role 
in their interaction and subsequent 
uptake into cells, and that the disruption 
of these proteins can influence their 
tissue uptake/localisation in vitro and in 
vivo [69, 71, 72]. DTPA-anhydride 
conjugation to exosomal surface proteins 
in the membrane labelling approach 
harbours such risk and could potentially 
influence the organ biodistribution of 
ExoB16. A dot blot analysis was carried 
out on the exosomes following a 
mock-radiolabelling protocol. It was 
found that surface proteins such as CD63 
and CD9 are still present on the 
exosomes post-labelling, but showed a 
lower signal intensity upon detection 
 
 
Figure 6. Blood circulation, excretion and organ biodistribution profile of 
membrane-labelled B16F10 exosomes in melanoma-bearing NSG mice. Animals were 
injected with 1x1011 [111In]DTPA-ExoB16 (0.5-1MBq). (A) Blood circulation profile of 
[111In]DTPA-ExoB16 in NSG mice. Blood (5 µl) was taken via tail bleeding at 2 min, 5 min, 10 min, 30 
min, 1 h, 4 h and 24 h following intravenous injection of exosomes. (B) Excretion profile of 
[111In]DTPA-ExoB16 in NSG mice where urine and faeces were collected from the animals 24 h 
post-injection. For (A) and (B), the values are plotted in comparison with that of C57BL/6 
presented in Fig. 5. (C) Organ biodistribution of [111In]DTPA-ExoB16 in NSG mice. Animals were 
culled at 1 h, 4 h and 24 h post-injection, perfused with saline and their organs were excised for 
analysis by gamma counting. Inset shows the zoomed-in tumour accumulation values for each group. 
(D) Comparison of organ biodistribution of [111In]DTPA-ExoB16 in C57Bl/6 and NSG mice 24 h 
post-injection, where inset shows zoomed-in tumour accumulation values for each group. Values are 
normalised to organ weight and expressed as mean ± SD, where n=3 for each group. For (C) and 
(D), statistical analyses were done on liver, spleen, kidneys and tumour (p*<0.05, p** < 0.01, p*** 
<0.001). 
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(Fig. S8). This is most probably due to the conjugated 
DTPA causing slight hindering of the antibody 
binding. Further studies have to be carried out to 
investigate whether this would influence exosome 
uptake and accumulation in tissues in vivo. 
In this study, ExoB16 showed rapid clearance 
from the circulation, accumulating predominantly in 
the liver and spleen. This accumulation profile is 
consistent with a number of other exosome 
biodistribution studies involving optical and nuclear 
modalities, where usually kidneys were reported to 
show the 3rd highest accumulation after the liver and 
spleen [19, 32-34, 73]. Other types of nanocarriers 
bearing physicochemical resemblance to exosomes 
such as liposomes and polymeric nanocapsules were 
also reported to accumulate mostly in the liver and 
spleen [57, 58, 61], which further supports the findings 
of this study. Lung accumulation is more commonly 
observed for non-spherical carbon-based nanocarriers 
with high aspect ratio or surface area such as carbon 
nanotubes and graphene [59, 74], but a number of 
studies using melanoma-derived exosomes however 
reported substantial exosome in the lungs. In two of 
these studies, B16-BL6 exosomes (murine melanoma) 
were engineered to express Gaussia luciferase (GL 
exosomes) and streptavidin (SAV-LA exosomes) 
respectively, showed prominent accumulation in liver 
and lungs [38, 40]. One study demonstrated that a 
high dose of exosomes administered intravenously 
resulted in asphyxia as a result of the exosome 
accumulation in the lungs [19]. However, the exosome 
dose administered in the former two studies (4-5 µg) 
were much lower than that of the latter (400 µg). 
Streptavidin was reported to naturally form tetramers 
in physiological conditions [75], and so the SAV-LA 
exosomes in the study could have formed aggregates 
from the interaction between the streptavidin 
molecules and accumulated in the lungs. However, 
the authors reported no size differences between the 
SAV-LA exosomes and unmodified ones from NTA 
analysis [40]. Size analysis however was not 
performed on the GL exosomes [38]. Another study, 
also using B16BL6 exosomes showed substantial lung 
accumulation, which was significantly reduced 
following the disruption of their exosomal surface 
proteins [72]. The surface protein disruption done in 
this study was by Proteinase K treatment for 30 
minutes, which resulted in major ablation of surface 
proteins on B16BL6 exosomes, compared to the milder 
disruption on the surface proteins of ExoB16 by DTPA 
incorporation in this study as discussed above. 
Therefore, the minimal lung accumulation of ExoB16 
observed in this study could not be attributed to the 
altered surface proteins. Although both B16BL6 and 
B16F10 are both melanoma-derived cell lines, the lung 
metastatic organotropism of the former was reported 
to be higher than that of the latter [76], thus it is likely 
that B16BL6 exosomes do home to the lungs to a 
greater extent than B16F10 exosomes. This is 
highlighted by a study that demonstrated exosomes 
derived from cancer cell lines with higher lung 
metastatic organotropism accumulated in lung tissues 
3 times higher than those derived from cell lines with 
other metastatic organotropisms such as liver, bone 
and brain [77]. Another study showed B16F10 
exosomes presence in lungs and bone marrow 
following intravenous administration, and that they 
induce greater metastasis of B16F10 cells to these sites 
compared to untreated controls [78]. However, the 
amount of exosomes present in these tissues were not 
properly quantified. To complicate the position 
further, exosome doses administered in these studies 
were expressed differently (i.e. in terms of particle 
number or µg protein), which does not allow direct 
comparison to the results in this work. This implies 
that the exosome doses administered in these studies 
may vary and was reported to also influence their 
biodistribution [33].  
Another study by Lai et al. using exosomes from 
HEK293 cells showed a completely different exosome 
biodistribution profile to the one presented in this 
work. HEK293-derived exosomes accumulated to the 
greatest extent in the kidneys, followed by the liver, 
lungs and spleen [39]. The HEK293 exosomes had 
their surface engineered to have fusion protein 
constructs consisting of a PDGF-transmembrane 
domain for anchoring on the exosomal membrane; a 
biotin acceptor peptide sequence (BAP) for biotinyla-
tion by an exogenously expressed bacterial biotin 
ligase; and Gaussia luciferase. The modified exosomes 
here also did not show size differences from the 
unmodified exosomes [39]. Again, this study 
highlights the probable effect of introducing 
additional moieties of relatively large size on 
exosomal membrane (e.g. luciferase and streptavidin) 
on the tissue tropism of exosomes in vivo, which 
concurs with the role of exosomal surface proteins on 
their tissue localisation discussed above. Substantial 
considerations are warranted when deciding on the 
modification status to be adapted for drug delivery 
applications, and it is therefore imperative that the 
biodistribution of engineered exosomes be compared 
with their unmodified counterparts to take into 
account any possible effect of the modification on 
their biodistribution, Thus, the membrane radiolabel-
ling approach proposed in this work would serve as 
an excellent tool for this purpose.  
Discrepancies between exosome biodistribution 
reported in the above studies including the results in 
this work could also be due to the different labelling 
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and imaging modalities used. Previous work from our 
group [58, 79] demonstrated the difference between 
the biodistribution of the PLGA nanocapsules labelled 
with DiR or radiolabelled with 111Indium, where 
nanocapsules labelled with DiR showed significantly 
higher lung accumulation as compared to the same 
nanocapsules which were radiolabelled by including 
5-10% PLGA-PEG-DTPA in the excipients during 
formulation (i.e. without post-synthesis surface 
modification as done in this current work). Live whole 
body SPECT/CT imaging showed that the 
radiolabelled nanocapsules had a substantial lung 
accumulation at 1 h post-injection, which then 
continued to decrease over time from 4 h to 24 h, and 
this was supported by the quantitative organ 
biodistribution values obtained by gamma counting. 
Given the non-specific dye exchange phenomenon 
between membranes associated with lipophilic dyes 
such as DiR and PKH67 described earlier, the lung 
accumulation of DiR-labelled nanocapsules observed 
after 24 h is likely to come from the dye exchanged 
from the labelled nanocapsules to lung tissue where 
they initially accumulated in the early timepoint 
before redistributing to other organs, and this 
exchanged dye probably accumulated in the lungs 
over time up to 24 h. This highlights the robustness 
and reliability of using the nuclear modality in 
assessing exosome biodistribution and is the main 
motivation in developing the novel exosome 
radiolabelling approaches described in this study. 
 There are reports on naive exosomes having the 
potential of adopting the homing properties of their 
parent cell in vivo [33] or home to self-tissue in vitro 
[71]. In another study, the ExoB16 in similar 
B16F10-bearing C57Bl/6 mice were reported to show 
tumour accumulation of ~3% total administered 
fluorescence [33]. A separate study using PC3 and 
MCF-7 exosomes also showed similar self-tissue 
accumulation of ~2% ID/gT [19]. In our hands, 
fluorescently-labelled B16F10 exosomes (Scheme S2 – 
supplementary information) showed a significantly 
higher uptake than GL261 (murine glioma) exosomes 
in B16F10 cells in vitro (Fig. S9), which suggests the 
self-homing potential of B16F10 exosomes. However, 
ExoB16 showed very low accumulation in B16F10 
tumours in vivo, of less than 1% ID/gT. This low 
tumour accumulation of naïve exosomes, has been 
attributed to the rapid clearance of exosomes from the 
circulation by resident macrophages in organs that 
form part of the reticuloendothelial system (RES). A 
study demonstrated that depleting macrophages in 
mice by liposomal clodronate prior to exosome admi-
nistration significantly increased their circulation time 
[80]. A separate study showed that by blocking the 
Scavenger Receptor Class A family (SR-A), a recently 
identified uptake receptor for exosomes in 
macrophages, liver accumulation of exosomes was 
significantly reduced while their circulation time 
increased, which led to a 3-fold increase in tumour 
accumulation in vivo [34]. Exosomes expressing CD47, 
which inhibits phagocytosis by macrophages upon 
binding to their SIRPα surface protein, were reported 
to have prolonged circulation time and resulted in 
better tumour uptake and ablation in vivo [81]. Flow 
cytometry analysis on ExoB16 showed that CD47 is 
expressed very minimally on their surface (Fig. S10), 
which corroborated with the observed rapid clearance 
of ExoB16 from the circulation. Similar analysis done 
on exosomes derived from other cancer and 
non-cancer cell lines suggested that CD47 is not a 
common marker of exosomes, and that this should be 
taken into account when interpreting the circulation 
profile of exosomes (Fig. S10). This highlights the 
importance of the endowment of active targeting 
moieties such as expression of targeting ligands as 
fusion constructs on exosomal surface proteins [15, 
31], as well as developing strategies to bypass the RES 
organs as described above for effective targeted in vivo 
delivery of exosomes to non-RES sites such as 
tumours. 
Immunodeficient mouse strains of various 
degrees of immune system impairment are used in 
studies involving human-derived tumour models to 
improve the engraftment success in mice. To date, the 
most immunodeficient mouse strain described is the 
NOD-scid ILR2γnull (NSG) mice, whereby the NOD- 
mutation renders their innate immune cells (particul-
arly macrophages and dendritic cells) defective; the 
scid-mutation results in absence of the adaptive 
immune cells (T- and B-cells) and complement 
system, and the complete null mutation of the IL2R 
gene results in the absence of NK-cells as well as 
global defective cytokine-dependent signalling [82, 
83]. In this study, although the B16F10 cells used to 
develop the subcutaneous tumour is of murine origin 
and therefore does not require an immunodeficient 
background for the host, NSG mice were chosen to 
serve as the extreme counterpart of the immunocom-
petent C57Bl/6 mice to investigate the influence of the 
immune system in ExoB16 biodistribution. In this 
study, ExoB16 biodistribution did not differ significan-
tly between the C57Bl/6 and the NSG mice. However, 
looking at the kinetics of ExoB16 accumulation in the 
RES organs of the NSG mice, the spleen initially 
recorded a lower signal, which increased by 3-fold 
between 4 h and 24 h to match that of the of the 
C57Bl6 mice (Fig. 6C). This delayed exosome 
accumulation in RES organs in immunodeficient mice 
was consistent with a study using NOD.CB17- 
Prkdcscid/J mice, and was attributed to the defective 
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complement activation in opsonisation and therefore 
less effective uptake by phagocytic cells in mice with 
NOD-mutation background [19]. 
Interestingly, tumours of the immunocompetent 
mice showed significantly higher accumulation of 
ExoB16 than that of the immunodeficient mice (Fig. 
6D). Given the difference in the immune background 
of both mice strains, it is hypothesised that the 
difference in tumour accumulation values is due to 
the difference in the proportion of tumour-associated 
macrophages (TAMs) present in the tumours. Flow 
cytometry analysis on the total cells isolated from 
subcutaneous B16F10 tumours (gating strategy is 
described in supplementary information and Fig. 
S11A) developed in both strains of mice showed that 
tumours from the immunodeficient NSG mice had a 
significantly smaller population of TAMs (CD45+ 
F4/80+ CD11b+) (Fig. S11B) compared to that of the 
tumours from C57Bl/6 mice, which supports the 
hypothesis above. This suggests that tumour accumu-
lation of exosomes in an immunodeficient host can be 
an underestimation compared to the actual value in 
an immunocompetent background. Therefore, it is 
important to relate the degree of immunity impair-
ment of the animal model used to the results obtained 
for a more contextual interpretation of the data which 
might affect factors such as dosing for future therapy 
studies. 
Conclusions 
The results in this work demonstrated that 
melanoma-derived exosomes were successfully and 
stably radiolabelled using a novel membrane radiola-
belling approach. This has enabled a quantitative 
analysis of their biodistribution to be carried out in 
melanoma-bearing immunocompetent mice, showing 
high accumulation in the liver and spleen from the 
early time points up to 24 h, with marginal tumour 
(i.e. self-tissue) accumulation. This membrane 
radiolabelling approach also enabled a quantitative 
biodistribution comparison of the same exosomes in a 
similar tumour model but established in immuno-
deficient mice and showed that defective immune 
system did not influence the exosome biodistribution 
in vivo with the exception of the degree of their 
accumulation in the tumours. This novel membrane 
radiolabelling method is therefore a simple, reliable 
and more importantly, has the potential of 
radiolabelling any type of exosomes, isolated from 
either primary or immortalised cell cultures, and even 
from physiological fluids without requiring any 
engineering on the exosomes. It is hoped that this 
work will serve as an impetus in achieving a more 
standardised approach to understanding the in vivo 
fate of the many different types of exosomes thus 
rendering these future studies more comparable given 
the heterogeneous nature of exosomes. Given the 
marginal self-tissue accumulation as opposed to the 
high RES-organ accumulation of naïve exosomes 
observed in this study, active targeting moieties 
appears to be essential to be imparted on exosomes 
for them to have a better prospect as an effective drug 
delivery system. Nonetheless, the in vivo biodistri-
bution of naïve exosomes should always be studied 
and compared to that of their engineered counterpart, 
and this work provides an excellent tool for such 
comparative studies to be done reliably and 
accurately. 
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